Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.67 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.67 |
| ▸ | USP2 | O75604 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4092472 | 0.87 | LMNA (0.67) | LMNAMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL413342 | 0.81 | CYP1A2 (1.00) | LMNAMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL14262815 | 0.81 | CYP1A2 (0.65) | LMNAMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL17372601 | 0.80 | ACP1 (0.51) | LMNAMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL414375 | 0.79 | LMNA (0.59) | LMNAMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL16404462 | 0.76 | ABCG2 (0.70) | MEN1KMT2AABCG2ABCB1EGFR | |
| SCHEMBL16404474 | 0.76 | ABCG2 (0.74) | MEN1KMT2ATP53MAPTABCG2 | |
| SCHEMBL15280232 | 0.74 | EGFR (0.76) | ABCG2EGFRKDRSLC2A1 | |
| SCHEMBL4847453 | 0.73 | ALDH1A1 (0.71) | LMNAMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL14474025 | 0.72 | ABCG2 (0.63) | LMNAMEN1KMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-7597884-B2 | Hyperglycosylated polypeptide variants and methods of use | ALIOS BIOPHARMA, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-2093235-A1 | Hyperglycosylated variants of interferon alfacon-1 | Alios Biopharma Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1789074-A4 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1987060-A2 | SYNTHETIC HYPERGLYCOSYLATED, AND HYPERGLYCOSYLATED PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | Alios Biopharma Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1575506-A4 | METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-BETA INHIBITORS | SCIOS INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-7345045-B2 | Pyrido-pyrimidine compounds as medicaments | SCIOS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1572208-A4 | METHOD FOR COUNTERACTING A PATHOLOGIC CHANGE IN THE BETA-ADRENERGIC PATHWAY | SCIOS INC (US) | 2007-08-29 | — | — | EP | disclosed |
| WO-2007092537-A2 | SYNTHETIC HYPERGLYCOSYLATED, AND HYPERGLYCOSYLATED PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2004010929-A2 | METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS | SCIOS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| WO-2003097615-A1 | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS | SCIOS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030069248-A1 | Quinazoline derivatives as medicaments | CHAKRAVARTY SARVAJIT (US) | 2003-04-10 | — | — | US | disclosed |
| US-6476031-B1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020161010-A1 | Quinazoline derivatives as medicaments | CHAKRAVARTY SARVAJIT (US) | 2002-10-31 | — | — | US | disclosed |
| CN-1333757-A | Quinazoline derivatives as medicaments | SCIOS INC (US) | 2002-01-30 | — | — | CN | disclosed |
| US-6277989-B1 | USEFUL IN TREATING CONDITIONS THAT ARE CHARACTERIZED BY ENHANCED P38 KINASE ACTIVITY AND/OR TRANSFORMING GROWTH FACTOR BETA (TGF-.BETA.) ACTIVITY SUCH AS INFLAMMATION, PROLIFERATIVE DISEASES, AND CERTAIN CARDIOVASCULAR DISORDERS | SCIOS, INC. | 2001-08-21 | — | — | US | disclosed |
| EP-1107959-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2001-06-20 | — | — | EP | disclosed |
| US-6184226-B1 | ANTIINFLAMMATORY AGENTS FOR TREATMENT OF CARDIOVASCULAR SYSTEM DISORDERS/RESPIRATORY SYSTEM DISORDERS, ANTIISCHEMIC AGENTS | SCIOS INC. | 2001-02-06 | — | — | US | disclosed |
| WO-2000012497-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161010-A1 | Quinazoline derivatives as medicaments | SMAD3, SMAD2, TGFBR1 | LMNA 2827/4885MEN1 1621/4885KMT2A 2523/4885 |
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | IFNAR1, IDE, CTSC | LMNA 3227/4885MEN1 3779/4885KMT2A 4519/4885 |
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | IFNAR1, EPOR, HBB | LMNA 2682/4885MEN1 3843/4885KMT2A 4668/4885 |
| US-20030069248-A1 | Quinazoline derivatives as medicaments | SMAD3, SMAD2, TGFBR1 | LMNA 2827/4885MEN1 1621/4885KMT2A 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.